{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:11:21Z","timestamp":1790824281679,"version":"4.1.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>von Willebrand factor (VWF) concentrates may be required for on-demand treatment (ODT) or long-term prophylaxis (LTP) in von Willebrand disease (VWD). This study assesses the cost-effectiveness of LTP compared with ODT in patients with VWD treated with Voncento in the United Kingdom. A Markov structure was developed to estimate the quality-adjusted life years (QALYs) and costs of VWD treatment over a lifetime horizon. Treatment options included ODT or LTP. For both options, we assumed plasma-derived VWF\/factor VIII 2.4:1 (Voncento) as the VWF product used. Clinical parameters were obtained from published literature and Voncento\u2019s summary characteristics. Utility weights were obtained from published literature. Costs (in 2021 GBP [\u00a3]) and outcomes were discounted annually by 3.5%. Sensitivity analyses were conducted. Three baseline annual bleed rate (ABR) scenarios (11, 26.5, and 39.6) were considered. In the base-case analyses, Voncento LTP resulted in lower costs (\u2013\u00a3831\u2009206) and greater QALYs (6.14) vs ODT. Savings were primarily due to reductions in product use required (\u2013\u00a3529\u2009571) and bleed-related other medical costs (\u2013\u00a3301\u2009352). Compared with ODT, LTP also resulted in 322.52 fewer major bleeds and 515.68 fewer minor bleeds over a lifetime horizon. Probabilistic sensitivity analyses showed dominance in 96.12% of simulations and cost-effectiveness in 97.68% of simulations. For the 39.6 ABR scenario also, LTP was dominant compared with ODT. Results suggest that Voncento LTP is more effective and cost saving than ODT in the United Kingdom for patients with VWD with higher ABR. Prophylaxis for patients with frequent bleeds is likely to be a cost-saving and effective strategy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014376","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T20:08:41Z","timestamp":1734552521000},"page":"1312-1319","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom"],"prefix":"10.1182","volume":"9","author":[{"given":"Michele","family":"Wilson","sequence":"first","affiliation":[{"name":"1RTI Health Solutions, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-1317","authenticated-orcid":false,"given":"Giancarlo","family":"Castaman","sequence":"additional","affiliation":[{"name":"2Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Will","family":"Thomas","sequence":"additional","affiliation":[{"name":"3Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Millar","sequence":"additional","affiliation":[{"name":"4Imperial College and Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-0381","authenticated-orcid":false,"given":"Gin\u00e9s","family":"Escolar","sequence":"additional","affiliation":[{"name":"5Department of Hematopathology, Centre Diagnostic Biomedic, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Miesbach","sequence":"additional","affiliation":[{"name":"6Haemophilia Centre, Medical Clinic II, Institute of Transfusion Medicine, Goethe University Hospital, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"McDade","sequence":"additional","affiliation":[{"name":"1RTI Health Solutions, Research Triangle Park, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radovan","family":"Tomic","sequence":"additional","affiliation":[{"name":"7CSL Behring, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songkai","family":"Yan","sequence":"additional","affiliation":[{"name":"8CSL Behring, King of Prussia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"1","key":"2025032512170337000_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1538-7836.2009.03661.x","article-title":"The prevalence of symptomatic von Willebrand disease in primary care practice","volume":"8","author":"Bowman","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2025032512170337000_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/bloodadvances.2020003265","article-title":"ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease","volume":"5","author":"James","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2025032512170337000_bib3","first-page":"175","article-title":"Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States","volume":"27","author":"Lu","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"suppl 2","key":"2025032512170337000_bib4","first-page":"e12589","article-title":"Burden of illness in patients with von Willebrand disease: a systematic review [abstract]","volume":"5","author":"Du","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 2","key":"2025032512170337000_bib5","first-page":"e12589","article-title":"Clinical, economic, and quality of life burden associated with von Willebrand disease (VWD) in adults and children: systematic and targeted literature reviews [abstract]","volume":"5","author":"Castaman","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2025032512170337000_bib6","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ajh.10327","article-title":"Health status and health-related quality of life associated with von Willebrand disease","volume":"73","author":"Barr","year":"2003","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032512170337000_bib7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1365-2516.2008.01901.x","article-title":"Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor\/factor VIII concentrate","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"2","key":"2025032512170337000_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MBC.0000000000000568","article-title":"Pharmacokinetics, efficacy, and safety of a plasma-derived VWF\/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study)","volume":"28","author":"Lissitchkov","year":"2017","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"suppl 1","key":"2025032512170337000_bib9","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.thromres.2006.01.021","article-title":"Clinical experience of prophylactic treatment in von Willebrand disease","volume":"118","author":"Lethagen","year":"2006","journal-title":"Thromb Res"},{"issue":"5","key":"2025032512170337000_bib10","first-page":"391","article-title":"A\u00a0phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease","volume":"17","author":"Peyvandi","year":"2019","journal-title":"Blood Transfus"},{"issue":"1","key":"2025032512170337000_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025032512170337000_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-136241","article-title":"Cost-effectiveness of long-term prophylaxis versus on-demand treatment with von Willebrand factor concentrate in severe inherited von Willebrand disease","volume":"136","author":"Bhaskar","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025032512170337000_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2010.029868","article-title":"A\u00a0modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A","volume":"96","author":"Fischer","year":"2011","journal-title":"Haematologica"},{"issue":"5","key":"2025032512170337000_bib14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1258\/rsmacta.43.5.528","article-title":"Association between joint bleeds and Pettersson scores in severe haemophilia","volume":"43","author":"Fischer","year":"2002","journal-title":"Acta Radiol"},{"key":"2025032512170337000_bib15","unstructured":"National Institute for Health and Care Excellence\n          . Guide to the methods of technology appraisal 2013. Accessed 3 December 2024. https:\/\/www.nice.org.uk\/process\/pmg9\/chapter\/foreword."},{"key":"2025032512170337000_bib16","unstructured":"United Kingdom Haemophilia Centre Doctors\u2019 Organisation\n          . UKHCDO annual report 2021 & bleeding disorder statistics for the financial year 2020\/21. Accessed 3 December 2024. http:\/\/www.ukhcdo.org\/home-2\/annual-reports\/."},{"issue":"4","key":"2025032512170337000_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2025032512170337000_bib18","author":"Joint Formulary Committee","year":"2021"},{"key":"2025032512170337000_bib19","unstructured":"National Health Service\n          . National cost collection 2018\/2019. Accessed 3 December 2024. https:\/\/www.england.nhs.uk\/national-cost-collection\/."},{"key":"2025032512170337000_bib20","unstructured":"National Health Service\n          . Health survey for England, 2019: data tables. Accessed 3 December 2024. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/health-survey-for-england\/2019\/health-survey-for-england-2019-data-tables."},{"key":"2025032512170337000_bib21","unstructured":"Rind\n              DM\n            , WaltonSM, AgboolaF, . Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value; final report. Institute for Clinical and Economic Review; 20 November 2020. Accessed 3 December 2024. https:\/\/icer-review.org\/material\/hemophilia-a-update-evidence-report\/."},{"issue":"1","key":"2025032512170337000_bib22","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O\u2019Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"issue":"11","key":"2025032512170337000_bib23","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2106\/00004623-199311000-00006","article-title":"The effect of elective total hip replacement on health-related quality of life","volume":"75","author":"Laupacis","year":"1993","journal-title":"J\u00a0Bone Joint Surg Am"},{"issue":"3","key":"2025032512170337000_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1185\/030079908X273048","article-title":"Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling","volume":"24","author":"Ballal","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"149","key":"2025032512170337000_bib25","first-page":"153","article-title":"A radiologic classification of hemophilic arthropathy","author":"Pettersson","year":"1980","journal-title":"Clin Orthop Relat Res"},{"key":"2025032512170337000_bib26","unstructured":"Voncento summary of product characteristics (SmPC). Accessed 3 December 2024. https:\/\/www.medicines.org.uk\/emc\/product\/5341\/smpc."},{"issue":"1","key":"2025032512170337000_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12955-018-1019-3","article-title":"Health-related quality of life impact of minor and major bleeding events during dual antiplatelet therapy: a systematic literature review and patient preference elicitation study","volume":"16","author":"Doble","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"2025032512170337000_bib28","unstructured":"Office for National Statistics\n          . National life tables--life expectancy in UK: 2017 to 2019. Accessed 3 December 2024. https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/nationallifetablesunitedkingdomreferencetables."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/6\/1312\/2359081\/blooda_adv-2024-014376-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/6\/1312\/2359081\/blooda_adv-2024-014376-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T12:28:17Z","timestamp":1742905697000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/6\/1312\/534656\/Cost-effectiveness-of-Voncento-prophylaxis-vs-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014376","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}